Literature DB >> 3130180

Efficacy of follow-up bone scans in carcinoma of the prostate.

D Corrie1, J H Timmons, J M Bauman, I M Thompson.   

Abstract

Three hundred fifteen radioisotopic bone scans ranging from initial scan only to nine scans per patient, performed on 114 patients with adenocarcinoma of the prostate between 1979 and 1984, were reviewed. Seventeen patients had positive scans, ten on initial scan and seven at follow-up. Nine patients had bone pain at the time of the first positive scan and pain developed in two patients 6 months and 2 years later, respectively. The other six patients are still asymptomatic 1 to 4 years later. False-positive scans were found in six other patients. No patient with bone pain had a negative scan. We believe that routine bone scans for prostate cancer follow-up are not cost-effective unless the patient is symptomatic. Bone scans also are indicated for initial staging and to observe disease response to protocol treatment.

Entities:  

Mesh:

Year:  1988        PMID: 3130180     DOI: 10.1002/1097-0142(19880615)61:12<2453::aid-cncr2820611211>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Imaging in the diagnosis and management of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

2.  Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy.

Authors:  G M Sundkvist; L Ahlgren; B Lilja; S Mattsson; P A Abrahamsson
Journal:  Eur J Nucl Med       Date:  1990

3.  Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.

Authors:  Naoto Kamiya; Hiroyoshi Suzuki; Takumi Endo; Makoto Takano; Masashi Yano; Makito Naoi; Koji Kawamura; Takashi Imamoto; Masaharu Takanami; Tomohiko Ichikawa
Journal:  Int J Clin Oncol       Date:  2011-02-16       Impact factor: 3.402

4.  Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.

Authors:  Ping Huang; Min Lan; Ai-Fen Peng; Qing-Fu Yu; Wen-Zhao Chen; Zhi-Li Liu; Jia-Ming Liu; Shan-Hu Huang
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.